About CellCentric
CellCentric is a Healthcare company based in Cambridge (United Kingdom) founded in 2003 by Azim Surani and Will West. It develops small molecule inhibitors to combat cancer. CellCentric has raised $210.3 million across 12 funding rounds from investors including Pfizer, RA Capital and BrightEdge. The company has 18 employees. Its chief executive is Will West. CellCentric offers products and services including Inobrodib. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is CELLCENTRIC LIMITED. Its competitors include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
The biotechnology company was founded in 2003 in Cambridge, United Kingdom, with a focus on cancer drug discovery rooted in epigenetics. Nearly 50 enzymes linked to epigenetic regulation have been identified and examined, and early drug discovery efforts have been conducted on six of them. An arginine methyltransferase program was developed, partnered, and subsequently licensed to Takeda Pharmaceuticals.
- Headquarters Cambridge, United Kingdom
- Employees 18
- Founders Azim Surani, Will West
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cellcentric.com
- Social LinkedIn X
- Legal Name Cellcentric Limited
- Date of Incorporation 30 Oct, 2003
- Jurisdiction CAMBRIDGE
- Total Equity Funding$210.3M (USD)
in 12 rounds
- InvestorsPfizer
& 13 more
- Employee Count18
Products & Services of CellCentric
CellCentric offers a comprehensive portfolio of products and services, including Inobrodib.
Small molecule inhibitor targeting p300/CBP for cancer cell growth disruption.
Funding Insights of CellCentric
CellCentric has successfully raised a total of $210.3M across 12 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $210.3M
- Total Rounds 12
- Investors Count 14
Latest 10 of 12 funding rounds of CellCentric with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | – | Series D | – | – | – |
| May 2025 | $120M | Series C | – | RA Capital Management, Forbion | |
| Jul 2024 | $35M | Series C | – | RA Capital Management | – |
| Jul 2023 | $25M | Series C | – | Pfizer | – |
| Jan 2022 | – | Series C | – | BrightEdge, Morningside | |
| May 2018 | $26M | Series C | – | – | |
| Jun 2013 | $7.3M | Grant | – | – | – |
| Mar 2013 | – | Series B | – | – | |
| Mar 2011 | – | Series B | – | – | |
| Oct 2007 | $4.3M | Series A | – | Takeda Ventures, Morningside |
14 investors in total: 14 institutional.
Investors in CellCentric
CellCentric has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, RA Capital and BrightEdge.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
BrightEdge is focused on impact investment in cancer care innovation. | – | brightedgefund.org | - | |
Multiple sectors are invested in by Morningside, a VC fund. | – | morningside.com | Newton, United States | |
A venture capital firm focused on technology and innovation investments. | – | 5ycap.com | Shanghai, China | |
Early-stage innovations are funded by UKI2S across key sectors. | – | ukinnovationscienceseedfund.co.uk | Manchester, United Kingdom | |
- | – | takedaventures.com | - | |
Impact investments are made in mission-led technology ventures. | – | nestainvestments.org.uk | London, United Kingdom | |
- | – | providenceinvestmentcompany.tcc.mode | - | |
- | – | avlar.com | - | |
Venture capital firm focused on lifescience and healthcare sectors | – | forbion.com | Naarden, Netherlands | |
Private equity investments are directed toward the healthcare sector. | – | avego.com | Alpharetta, United States |
Investor details for CellCentric
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CellCentric
8 people are tracked at CellCentric (4 in leadership, 4 in team); the tracked headcount is 18.
| Name | Role | Group |
|---|---|---|
Azim Surani | Co-Founder | Leadership |
Will West | Co-Founder & CEO | Leadership |
Debbie Haynes | Chief Operating Officer | Leadership |
Karen Clegg | Clinical Science Director | Leadership |
Fay Ashby | Senior Clinical Trials Manager | Team |
Ruth Tysoe | Clinical Trial Manager | Team |
Gail Millward | Contract Clinical Research Associate | Team |
Carrie Walker | Clinical Trial Administrator | Team |
Complete people profiles for CellCentric
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CellCentric
3 dated milestones of CellCentric across 23 years, from founding to its latest funding, stage changes and deals.
- Founded CellCentric is founded.
- Funding First funding round.
- Funding Latest funding round, Series D,.
Competitors of CellCentric
CellCentric has 9 listed competitors in our database, 8 of them funded. They include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of CellCentric
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CellCentric
The website of CellCentric (cellcentric.com) receives about 5.5K visits a month.
- Monthly visits5.5K
▼ 8.7% vs previous month
Websites whose visitors overlap most with CellCentric. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
epidna.com | epidna.com | 100% | – | – | – |
epigenome-noe.net | epigenome-noe.net | 100% | – | #1,408,060 | – |
epigeneticsnews.com | epigeneticsnews.com | 100% | – | – | – |
epigeneticstation.com | epigeneticstation.com | 100% | – | – | – |
epigenie.com | epigenie.com | 99% | – | #3,077,943 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for CellCentric
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
10 companies that operate in the same segment as CellCentric (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cellcentric
Complete news archive for CellCentric
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CellCentric
CellCentric was founded in 2003.
CellCentric is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Will West is the current CEO of CellCentric. They have also founded this company.
CellCentric is a funded company, having raised a total of $210.3M across 12 funding rounds to date. The company's 1st funding round was a Series A of $4.3M, raised on Jun 2003.
CellCentric has 18 employees.
The biotechnology company was founded in 2003 in Cambridge, United Kingdom, with a focus on cancer drug discovery rooted in epigenetics. Nearly 50 enzymes linked to epigenetic regulation have been identified and examined, and early drug discovery efforts have been conducted on six of them. An arginine methyltransferase program was developed, partnered, and subsequently licensed to Takeda Pharmaceuticals.
CellCentric's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
CellCentric offers Inobrodib.
CellCentric has 14 investors. Key investors include Pfizer, RA Capital, BrightEdge, Morningside, and 5Y Capital.
CellCentric operates through Cellcentric Limited.